Novo Nordisk : $ 7bn in capitalisation created for a very risky project, 4-5 years from market, too much in our view
>Oral semaglutide will be the subject of 2 phase III trials in Alzheimer’s - Novo Nordisk announced during trading yesterday that it had decided to launch a programme of phase III trials to evaluate its GLP-1 oral semaglutide in Alzheimer’s disease. Note that Novo has already been selling the oral formulation of this compound in diabetes since 2019 under the brand name Rybelsus and that in our view it is set to be the main driver of the group’s growth out to 2025 (3/...Novo-Nordisk is a global healthcare company engaged in the innovation of diabetes care. Co. also provides haemophilia care, growth hormone therapy and hormone replacement therapy. The Diabetes care business segment includes research, development, manufacturing and marketing of products within the areas of insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD) and obesity. The Biopharmaceuticals business segment includes research, development, manufacturing and marketing of products within the areas of haemophilia, growth hormone therapy, hormone replacement therapy, inflammation therapy and other therapy areas.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.